By David Wild
Originally published by our sister publication, Gastroenterology & Endoscopy News
Las Vegas—Treatment with biologics and immunosuppressants does not increase the risk for cancer progression or recurrence in patients with inflammatory bowel disease and a history of active or recent, prior cancer, according to a new study.
This new research adds to a growing body of evidence supporting the safety of these drugs in an aging population of IBD patients. “With an aging